Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Pulmongene Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05895565
- Locations
- 🇨🇳
Site 07, Hefei, Anhui, China
🇨🇳Site 01, Beijing, Beijing, China
🇨🇳Site 06, Guangzhou, Guangdong, China
A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015
Phase 1
Completed
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Drug: PMG1015 Dose 2Drug: PMG1015 Dose 3Drug: PMG1015 Dose 1Drug: PMG1015 Dose 5Drug: PMG1015 Dose 4Drug: PMG1015 Dose 6Drug: PlaceboDrug: PMG1015 Dose 7
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- Pulmongene Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT05022771
- Locations
- 🇦🇺
Q-Pharm Pty Ltd, Clive Berghofer Cancer Research Centre, Herston, Queensland, Australia
News
No news found